1. |
Fleissig A, Fallowfield LJ, Langridge CI, et al. Postoperative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer [J]. Breast Cancer Res Treat, 2006; 95(3): 279293.
|
2. |
Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinelnode biopsy with routine axillary dissection in breast cancer [J]. N Engl J Med, 2003; 349(6): 546553.
|
3. |
Julian TB, Krag D, Brown A, et al. Preliminary technical results of NSABP B32, a randomized phase Ⅲ clinical trial to compare sentinel node resection to conventional axillary dissection in clinically nodenegative breast cancer patients [J]. Breast Cancer Res Treat, 2004; 88(Suppl 1): s11s12.
|
4. |
Helyer LK, Coburn NG, Law CH, et al. Axillary staging is more accurate today than ever before: no increase in the false negative rate with widespread adoption of sentinel node technique [J]. Breast Cancer Res Treat, 2007; 106(Suppl 1): s127s128.
|
5. |
Filippakis GM, Zografos G. Contraindications of sentinel lymph node biopsy: are there any really? [J]. World J Surg Oncol, 2007; 5(1): 1020.
|
6. |
Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in earlystage breast cancer [J]. J Clin Oncol, 2005; 23(30): 77037720.
|
7. |
Silverstein MJ, Lagios MD, Recht A, et al. Imagedetected breast cancer: state of the art diagnosis and treatment [J]. J Am Coll Surg, 2005; 201(4): 586597.
|
8. |
Carlson RW, Anderson BO, Burstein HJ, et al. NCCN breast cancer clinical practice guidelines in oncology. Version 1, 2009. Available at: http: //www.nccn.org/physician_gls/ PDF/breast.pdf. Accessed January 25, 2009.
|
9. |
Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 [J]. Ann Oncol, 2007; 18(7): 11331144.
|
10. |
王永胜. 乳腺癌局部区域治疗: 进展与共识 [J]. 中国医学论坛报, 2009; 35(12): B2.
|
11. |
Bleiweiss IJ, Nagi CS, Jaffer S. Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma [J]. J Clin Oncol, 2006; 24(13): 20132018.
|
12. |
Alberti S, Querzoli P, Pedriali M, et al. Axillary lymph node nanometastases are prognostic factors for metastatic relapse in breast cancer patients [J]. Breast cancer Res Treat, 2006; 100(Suppl 1): s13.
|
13. |
de Boer M, van Deurzen CH, van Dijck JA, et al. Micrometastases and isolated tumor cells: relevant and robust or rubbish? (MIRROR): preliminary results of the MIRROR study from the Dutch breast cancer trialists’ group (BOOG) [J]. Cancer Res, 2009; 69(Suppl 2): 70s.
|
14. |
Coutant C, Houvenaeghel G, Olivier C, et al. Validation and comparison of nomograms and scores to predict nonsentinel lymph node status in breast cancer patients with metastatic .
|
15. |
Gur SA, Unal B, Johnson R, et al. The predictive probability of four different breast cancer nomograms for nonsentinel axillary lymph node metastasis in positive sentinel lymph node biopsy [J]. Cancer Res, 2009; 69(Suppl 2): 86s.
|
16. |
Blumencranz P, Deck KB, Whitworth PW, et al. Multiplex molecular assay has inproved sensitivity over histological intraoperative node metastases tests for breast cancer patientsresults from a large multicenter trial [J]. Breast cancer Res Treat, 2006; 100 (Suppl 1): s14.
|
17. |
Blumencranz P, Deck KB, Whitworth PW, et al. High sensitivity of a molecular assay for breast metastases in sentinel lymph nodes that are difficult to detect by frozen section [J]. Breast cancer Res Treat, 2007; 106(Suppl 1): s15.
|
18. |
Kissin MW, Snook KL, Layer GT, et al. Intraoperative molecular sentinel lymph node analysis with OSNA: multicenter prospective UK evaluation [J]. Cancer Res, 2009; 69 (Suppl 2): 104s.
|